Sugerencias
Idioma
Información de la revista
Cita
Cita
Compartir
Descargar PDF
Más opciones de artículo
Visitas
395
Review
Acceso a texto completo
Disponible online el 9 de octubre de 2026

The “Trojan horse” against antimicrobial resistance: Siderophore conjugates and public health

El «caballo de Troya» contra la resistencia antimicrobiana: conjugados siderofóricos y salud pública
Visitas
395
Alina Dammar Herrera-Callo
Autor para correspondencia
aherrerac@unf.com.pe

Corresponding author.
, Marco Roberto Chávez-Morán
Facultad de Industrias Alimentarias y Biotecnología, Universidad Nacional de Frontera, Piura, Peru
Contenido relacionado
Alina Dammar Herrera-Callo, Marco Roberto Chávez-Morán
Este artículo ha recibido
Información del artículo
Resumen
Texto completo
Bibliografía
Descargar PDF
Estadísticas
Figuras (3)
f0005
f0010
f0015
Tablas (3)
Table 1. Bacterial siderophores: pathogenicity and therapeutic applications.
Tablas
Table 2. Siderophore-drug conjugates and their clinical applications.
Tablas
Table 3. Siderophore–drug conjugates versus siderophore–peptide conjugates.
Tablas
Abstract
Objective

Antimicrobial resistance, particularly in carbapenemase-producing Enterobacterales such as KPC-type, represents a critical threat to public health in Latin America, associated with high mortality rates and increased healthcare costs. This systematic review aims to evaluate the therapeutic potential of siderophore-drug and siderophore-peptide conjugates against priority multidrug-resistant pathogens, including Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii, analyzing their efficacy, mechanisms of action, and implementation challenges.

Method

A systematic search was conducted in the PubMed, Scopus, and Web of Science databases up to August 2025. Key terms such as “siderophore conjugates”, “Trojan horse antibiotics”, “antimicrobial resistance”, and “Gram-negative bacteria” were used. Preclinical and clinical studies, reviews, and meta-analyses published between 2019 and 2025 were included, selecting 55 references based on relevance to the topic, currency, and methodological quality. This review is a narrative review with a systematic literature search, developed in accordance with PRISMA guidelines.

Results

Siderophore conjugates, via the “Trojan horse” mechanism, effectively exploit bacterial iron uptake systems to deliver antimicrobial agents in a targeted manner. They overcome key resistance mechanisms such as β-lactamase production, porin alterations, and efflux pump activity, while reducing systemic toxicity and preserving commensal microbiota. Clinical evidence (e.g., cefiderocol) and preclinical studies confirm their efficacy against multidrug-resistant (MDR) and extensively drug-resistant (XDR) strains, achieving significant reductions in minimum inhibitory concentrations (MICs). However, critical challenges were identified: optimization of chemical stability and intracellular drug release, complexity in synthesis and industrial scaling under Good Manufacturing Practice (GMP) standards, and regulatory and logistical barriers in resource-limited settings.

Conclusions

Siderophore conjugates offer a targeted therapeutic approach against multidrug-resistant pathogens by exploiting the bacteria's own iron-uptake systems. The available evidence ranges from clinical results with cefiderocol to preclinical developments with other platforms. Their application, however, faces challenges that span chemical optimization, manufacturing, regulation, and access in clinical settings.

Keywords:
Drug resistance, bacterial
Siderophores
Drug-siderophore conjugates
Siderophore-peptide conjugates
Public health
Resumen
Objetivo

la resistencia antimicrobiana, particularmente en enterobacterias productoras de carbapenemasas tipo KPC, representa una amenaza crítica para la salud pública en América Latina, con alta mortalidad y costos asociados. Esta revisión sistemática tiene como objetivo evaluar el potencial terapéutico de los conjugados sideróforo-fármaco y sideróforo-péptido frente a patógenos prioritarios multirresistentes, como Enterobacterales, Pseudomonas aeruginosa y Acinetobacter baumannii, analizando su eficacia, mecanismos de acción y desafíos de implementación.

Método

se realizó una búsqueda sistemática en las bases de datos PubMed, Scopus y Web of Science hasta agosto de 2025, utilizando términos clave como «siderophore conjugates», «Trojan horse antibiotics», «antimicrobial resistance» y «Gram-negative bacteria». Se incluyeron estudios preclínicos, clínicos, revisiones y metaanálisis publicados entre 2019 y 2025, seleccionando 55 referencias basadas en criterios de relevancia temática, actualidad y calidad metodológica. Esta revisión corresponde a una revisión narrativa con búsqueda sistemática de la literatura, desarrollada conforme a los lineamientos PRISMA.

Resultados

los conjugados siderofóricos, mediante el mecanismo «caballo de Troya», explotan eficazmente los sistemas bacterianos de captación de hierro para administrar agentes antimicrobianos de forma dirigida. Demostraron superar mecanismos de resistencia clave, como la producción de β-lactamasas, las alteraciones de porinas y las bombas de eflujo, con reducción de la toxicidad sistémica y preservación de la microbiota comensal. La evidencia clínica (cefiderocol) y preclínica confirma su eficacia frente a cepas multirresistentes (MDR) y extensamente resistentes (XDR), con reducciones significativas en la CIM (concentración inhibitoria mínima). Sin embargo, se identificaron desafíos críticos: optimización de la estabilidad química y de la liberación intracelular, complejidad en la síntesis y el escalado industrial bajo normas BPC, y barreras regulatorias y logísticas en entornos con recursos limitados.

Conclusiones

los conjugados siderofóricos ofrecen un enfoque terapéutico dirigido frente a patógenos multirresistentes al explotar los propios sistemas bacterianos de captación de hierro. La evidencia disponible abarca desde los resultados clínicos con cefiderocol hasta desarrollos preclínicos con otras plataformas. Su aplicación, no obstante, tropieza con desafíos que van desde la optimización química y la producción hasta la regulación y el acceso en entornos clínicos.

Palabras clave:
Resistencia bacteriana a los antimicrobianos
Sideróforos
Conjugados fármaco-sideróforo
Conjugados péptido-sideróforo
Salud pública
Texto completo
Introduction

Antimicrobial resistance (AMR) is one of the most critical global health threats of the 21st century. According to recent estimates, resistant bacterial infections caused 1.27 million direct deaths and were associated with a further 4.95 million deaths in 2019.1 This crisis has been exacerbated by the stagnation in the development of new classes of antibiotics over the past two decades, resulting in a critical therapeutic gap.2,3

The convergence of rising resistance and limited innovation calls for urgent alternative strategies. KPC-type carbapenemase-producing Klebsiella pneumoniae, which is associated with epidemic clones such as ST258, exemplifies this challenge: it causes nosocomial infections with high mortality rates in immunocompromised patients, for whom treatment options are severely limited.4–6

Data from the Global Burden of Disease confirm the upward trend: 4.71 million deaths were associated with AMR in 2021 (1.14 million directly attributable).Carbapenem resistance was the leading driver of this increase, rising from 619,000 associated deaths in 1990 to over 1 million in 2021.7 Projections for 2050 suggest that Latin America and South Asia will bear the highest burden of mortality.8 This scenario has been further aggravated in Latin America by the spread of KPC/NDM-co-producing Enterobacterales and the excessive use of antibiotics during the COVID-19 pandemic.9

Even in high-income countries, the limited access to innovative therapies underscores the need for sustainable alternatives. Among these, the use of siderophores as “Trojan horse” vectors is particularly notable: their intrinsic iron-chelating capacity enables targeted internalization of antimicrobials, thereby reducing selective pressure on the microbiota.10,11 Cefiderocol, a siderophore cephalosporin containing a catechol moiety, exemplifies this approach, demonstrating clinical efficacy against multidrug-resistant Enterobacterales, Pseudomonas, and Acinetobacter.12 Similarly, the development of siderophore–peptide conjugates that can enhance cellular permeability and overcome bacterial evasion mechanisms represents a new frontier in the design of functional antibiotics.13

Against this backdrop, several strategies targeting iron metabolism have been explored as potential alternatives. One such strategy is the use of gallium as a functional analogue of ferric iron which has attracted attention due to its ability to interfere with essential iron-dependent redox processes in bacteria. Similarly, chelation approaches aimed at restricting iron bioavailability in the infectious microenvironment have likewise been investigated.14 However, both strategies have limitations in terms of specificity and clinical efficacy, which has driven the development of more targeted approaches.

In light of the foregoing, this narrative review — conducted through a systematic literature search — aims to explore the potential of siderophore system as a therapeutic target. It also aims to evaluate the potential of siderophore–drug and siderophore–peptide conjugates together with the challenges associated with their clinical implementation. Finally, it aims to analyze the public health impact of KPC-mediated resistance.

Methods

The present study is designed as a narrative review with a systematic literature search, conducted in accordance with PRISMA guidelines. A search was performed in indexed scientific databases (Scopus, Web of Science, and ScienceDirect) from 2019 to 2025, supplemented by other relevant sources, using combinations of keywords related to siderophore conjugates and antimicrobial resistance.

The study selection process comprised four phases (identification, screening, eligibility, and inclusion). A total of 130 records were identified, comprising studies from databases (n = 120) and supplementary sources (n = 10). After removing duplicates (n = 30), 100 records were evaluated based on their titles and abstracts, and 60 of these were excluded due to a lack of relevance. Subsequently, 40 articles were reviewed in full text, of which 15 were excluded based on methodological or quality criteria. This resulted in 25 studies included in the qualitative synthesis. The complete flowchart is presented in Fig. 1.

Figure 1.

Flowchart of the study selection process. The study screening and selection process is detailed in accordance with the PRISMA statement. Of a total of 130 records initially identified, duplicates (n = 30) were removed, and records were excluded based on title and abstract (n = 60). After evaluating 40 full-text articles, 15 were excluded due to thematic or methodological criteria, resulting in 25 final studies included in the qualitative synthesis.

Preclinical and clinical studies, systematic reviews, and meta-analyses published in English or Spanish were included, provided that full-text access was available and they were directly relevant to the topic under review. Duplicates, non-peer-reviewed literature, conference abstracts, short communications without complete data, and studies unrelated to siderophore mechanisms were excluded.

The methodological quality of the studies was assessed qualitatively, considering the clarity of the design, internal validity, and relevance of the studies, with priority given to clinical evidence and recent systematic reviews. The manuscript included a total of 55 references, covering both the selected studies and supplementary literature.

Results

This review reveal that KPC-type carbapenemase-producing Enterobacterales resistance pose a significant public health risk. This issue is analyzed here in the context of bacterial iron acquisition mechanisms and novel siderophore conjugate-based therapeutic strategies.

Impact of KPC (Klebsiella pneumoniae Carbapenemase) on public health

KPC-type carbapenem-resistant Enterobacteriaceae (KPC-CRE) represent a global public health crisis of the first order, drastically curtailing therapeutic options in serious infections. This is reflected in an overall case fatality rate of 41%, rising to 56% among oncological patients and 51% in Brazil.15

This trend correlates with the approximately 800,000 deaths attributed to K. pneumoniae in 2019, disproportionately concentrated in resource-limited settings.7 At the same time, the emergence of hypervirulent and resistant strains (CR-hvKp) amplifies the threat, and their global spread is now well documented.16,17

In Europe, carbapenem resistance in K. pneumoniae exceeds 60% in tertiary care hospitals and is associated with treatment failure and a mortality rate of over 50%.18,19 Recognizing the severity of the situation, the World Health Organization (WHO) classifies these pathogens as “critical,” while projections estimate 10 million annual deaths and economic losses of more than 100 trillion USD by 2050.8,20

In Latin America, the endemicity of KPC leads to longer hospital stays and multiplies healthcare costs by two to four times. This phenomenon is particularly acute in ICUs, where patients with CRKP face nearly double the costs and longer hospitalizations (exceeding 13 days) compared to patients with antibiotic-susceptible infections. This pattern is replicated in Japan, where carbapenem-resistant infections have likewise been associated with significant economic and clinical burden.4,21–23 In addition to its inclusion in the ESKAPE group, 3 factors exacerbate the crisis: the rapid emergence of resistant clones; structural limitations in infection control; and unequal access to innovative antimicrobials in vulnerable settings.

Hence, understanding the iron acquisition system—a central mechanism of virulence and immune evasion in K. pneumoniae—provides the rational basis for developing therapies based on siderophores as targets of high strategic value.

The siderophore system as a virulence factor

Iron, an element essential for bacterial survival, is actively sequestered in the host by proteins such as transferrin and lactoferrin, constituting a nutritional immunity mechanism that drastically limits its bioavailability.24,25

Faced with this barrier, priority pathogens such as Klebsiella pneumoniae, Pseudomonas aeruginosa, and Acinetobacter baumannii have evolved high-affinity Fe3⁺ siderophore systems that are integrated into regulatory networks promoting tissue colonization, biofilm formation, and immune evasion.26,27 Notably, hypervirulent strains deploy a redundant siderophore arsenal, including enterobactin, aerobactin, yersiniabactin, and salmochelin, conferring them extreme adaptive plasticity. Genomic studies have shown that siderophore-encoding genes frequently co-localize with antimicrobial resistance determinants (e.g. β-lactamases and efflux pumps), facilitating the co-transfer of virulence and multidrug resistance. 28,29

The specificity of outer membrane receptor binding and the efficiency of siderophore-mediated transport have enabled the exploitation of these systems as Trojan-horse vehicles for the targeted delivery of antibiotics or antimicrobial peptides. (Table 1).30 However, this strategy faces critical challenges: (1) strain- and environment-dependent variability in receptor expression; (2) hierarchical environmental regulation; and (3) compensatory mutations that impair siderophore uptake.31

Table 1.

Bacterial siderophores: pathogenicity and therapeutic applications.

Siderophore-producing bacterium  Siderophore  Role in pathogenicity  Therapeutic target 
E. coli,K. pneumoniae  Enterobactin 
  • •

    High affinity for Fe3⁺

  • •

    Essential for growth in blood and systemic dissemination

 
FepA 
Yersinia pestis,K. pneumoniae  Yersiniabactin 
  • •

    Facilitates tissue invasion

  • •

    Innate immunity evasion

 
FyuA 
K. pneumoniae,E. coli  Aerobactin 
  • •

    Associated with hypervirulent strains

  • •

    Promotes replication in iron-limited environments

 
IutA 
Salmonella spp.,K. pneumoniae  Salmochelin 
  • •

    A variant of enterobactin that evades neutralization via lipocalin-2

 
IroN 
Pseudomonas aeruginosa  Pyoverdin 
  • •

    Facilitates pulmonary colonization

  • •

    Plays a key role in chronic infections

 
FpvA 
Acinetobacter baumannii  Acinetobactin 
  • •

    Essential for biofilm formation

  • •

    Promotes persistence on hospital surfaces

 
BauA 

These findings place siderophore systems at a critical crossroads: they are key drivers of bacterial virulence, yet they also expose structural and regulatory vulnerabilities that can be therapeutically exploited. The absolute dependence on these mechanisms during infection, coupled with the accessibility of their membrane receptors, makes iron metabolism a particularly attractive target for intervention in the context of growing antimicrobial resistance. Building on this foundation, current therapeutic strategies have focused on two complementary fronts: the development of siderophore-antibiotic conjugates that exploit active transport as a “Trojan horse” mechanism, and the design of inhibitors that block bacterial iron uptake.

Siderophore-drug conjugates

Siderophore-drug conjugates are a bio-inspired strategy that exploits bacteria's dependence on iron to overcome resistance barriers. These hybrids use iron transport systems as “Trojan horses” to internalize antimicrobial agents, circumventing resistance mechanisms such as porin modifications or efflux pumps (Fig. 2).13,30

Figure 2.

Schematic representation of the development of siderophore-drug conjugates for targeting KPC-producing bacteria. The diagram illustrates the integration of the public health impact, the bacterial iron uptake pathway, and the siderophore-drug conjugate strategy to achieve a targeted therapeutic effect.32

The clinical value of this strategy was demonstrated by cefiderocol. This is a siderophore cephalosporin that bears a catechol moiety that has shown efficacy against multidrug-resistant Enterobacterales, Pseudomonas, and Acinetobacter (Table 2). This molecule is highly stable against class A, B, and D β-lactamases, including carbapenemases such as KPC, NDM, and OXA-48.33,34 In clinical studies, cefiderocol has demonstrated efficacy in the treatment of complicated urinary tract infections (cUTI), hospital-acquired pneumonia (HABP), and bacteraemia caused by carbapenem-resistant Enterobacterales.35 Its iron receptor-mediated mechanism of entry allows it to bypass resistance mechanisms associated with porin loss and efflux pumps. (Fig. 3).10

Table 2.

Siderophore-drug conjugates and their clinical applications.

Drug  Type  Status  Clinical applications 
Cefiderocol  Siderophore + cephalosporin  Approved (FDA, 2019; EMA, 2020; Phase II–III trials: APEKS-cUTI, APEKS-NP, CREDIBLE-CR) 
  • •

    Treatment of cUTI, HABP/VABP caused by susceptible Gram-negative bacteria

  • •

    Infections caused by multidrug-resistant bacilli36

 
Albomycins  Natural sideromycin (albomycin class)  Preclinical (in vitro and in vivo evidence; no clinical trials reported) 
  • •

    Potential for potent, narrow-spectrum therapy

  • •

    Template for synthetic analogs37

 
MECAM-daptomycinDOTAM-daptomycin  Siderophore + lipoantibacterial peptide  Preclinical (proof-of-concept in experimental models) 
  • •

    Repurposing Gram-positive antibiotics for activity against Gram-negative bacteria

  • •

    Potential for use in XDR infections38

 
Aztreonam conjugate  Siderophore + monobactam  Preclinical (reported structural optimization, no clinical phase) 
  • •

    Broadening the spectrum against resistant strains

  • •

    Strategy against MBL-producing bacteria39

 
Conjugated ciprofloxacin  Siderophore + fluoroquinolone  Preclinical (in vitro/in vivo evaluation) 
  • •

    Improve intracellular uptake

  • •

    Reduction in systemic doses13

 
TAFC-[68Ga]DFO-[68Ga]  Radiolabelled siderophore (radiopharmaceutical)  Preclinical–early exploratory phase (molecular imaging) 
  • •

    Diagnosis of deep-seated infections (PET/SPECT)

  • •

    Monitoring of conjugate delivery40

 

Abbreviations: cUTI, complicated urinary tract infections; HABP/VABP, hospital-acquired pneumonia/ Ventilator-associated bacterial pneumonia; XDR, extensively drug-resistant; MBL, Metallo-Beta-Lactamase.

Figure 3.

Iron uptake and the Trojan horse therapeutic strategy in bacteria. Left (natural pathway): the siderophore binds to a specific receptor and is internalized by active transport, releasing Fe3⁺, which is reduced to Fe2⁺ in the cytoplasm. Right (therapeutic strategy): a siderophore-drug conjugate exploits this transport system to enter the bacterial cell and evade resistance mechanisms. Following internalization, the active compound is released and exerts its antimicrobial action.32

However, the clinical profile of cefiderocol has been the subject of debate following the results of the phase III CREDIBLE-CR trial. This trial showed an increase in all-cause mortality in the cefiderocol treatment arm compared with the best available therapy arm, particularly in infections caused by Acinetobacter baumannii.41 This finding has been partly attributed to imbalances in patients' baseline disease severity and to the clinical heterogeneity of the study population. No direct causal relationship has been established between these factors and the efficacy of cefiderocol.42

In response to these limitations and the need to optimize the therapeutic use of iron-mediated transport, the field of siderophore conjugates has diversified into two complementary approaches: (a) the synthetic design of siderophores conjugated to different classes of antibiotics (e.g. monobactams, rifamycins, and fluoroquinolones), which requires optimization of the covalent linker to ensure extracellular stability and intracellular release; and (b) siderophore–peptide conjugates that deliver antimicrobial peptides (AMPs) to the periplasm, thereby enhancing their activity and reducing proteolytic degradation. These approaches have shown a significant reduction in the minimum inhibitory concentration (MIC) in preclinical models against extensively drug-resistant (XDR) strains.11,13 In addition, siderophores offer potential applications as diagnostic probes and as radionuclide or fluorophore labels for PET/SPECT imaging. This complements therapeutic strategies by enabling the localization of infectious foci and the monitoring of intracellular delivery.43,44

Siderophore-peptide conjugates

Another compelling approach involves the use of siderophore–peptide conjugates, which combine active transport with the antimicrobial activity of antimicrobial peptides (AMPs). These conjugates represent a promising strategy against priority pathogens by combining selective internalization mediated by bacterial iron receptors with the membrane-lytic or immunomodulatory activity of AMPs. This synergistic approach enhances penetration into Gram-negative bacteria, protects against proteolytic degradation, increases bioavailability, and directs antimicrobial activity to the site of infection.11,45 However, it is important to note that most of these developments remain at the preclinical or proof-of-concept stage, with limited evidence from controlled clinical studies.

On the one hand, AMPs—which are cationic and amphipathic molecules—have demonstrated efficacy against polymicrobial biofilms and multidrug-resistant strains, as well as synergistic activity with conventional antibiotics. However, their progression from preclinical research to clinical application has been hampered by metabolic instability, hemolytic toxicity, and suboptimal systemic distribution.46

Covalent conjugation to siderophores (catecholates or hydroxamates) uses bacterial iron uptake pathways as a targeted entry mechanism, thus avoiding extracellular inactivation (Table 3). This principle is exemplified by natural systems such as the catecholate-modified microcins produced by Escherichia coli and Klebsiella pneumoniae. In the synthetic setting, conjugates such as FU002 (vancomycin–cationic peptide) have achieved up to a 1000-fold increase in activity against methicillin-resistant Staphylococcus aureus (MRSA).45,47 However, these results predominantly derived from in vitro or in vivo animal models, limiting their direct extrapolation to a clinical setting.

Table 3.

Siderophore–drug conjugates versus siderophore–peptide conjugates.

Overview  Siderophore–drug conjugates  Siderophore–peptide conjugates 
Mechanism  Antibiotic bound to siderophoreUptake via iron receptors  Peptide bound to siderophoreUptake via iron receptors 
Action  Inhibits cell wall or DNA synthesisDirect bactericidal effect  Membrane damageImmunomodulatory action 
Target pathogens  PrimarilyGram-negative  Gram-negative and Gram-positive (in some cases)Biofilms 
Advantages  High selectivityLow toxicityPreserves microbiota  Stability of AMPsLower degradationSynergy with antibiotics 
Limitations  Complex synthesisReceptor variability  Possible hemolytic toxicityHigh synthesis cost 
Bacterial resistance  Associated with alterations in siderophore receptors or their expression.Clinical evidence  Less likely due to multiple modes of action Preclinical evidence 
Status  Approved and in clinical trials  Primarily preclinical 

Furthermore, incorporating these conjugates into nanotechnology-based delivery systems (liposomes, polymeric nanoparticles, and hydrogels) is designed to improve molecular stability, enable controlled spatiotemporal release, and enhance their safety profile.48,49 Despite their potential, these approaches are in the early stages of experimentation and require validation in clinical studies before therapeutic implementation.

These targeted delivery systems are a promising therapeutic approach that could help reduce dysbiosis of the commensal microbiota, decrease selective pressure, and mitigate the emergence of antimicrobial resistance. To achieve this, three elements must be integrated: the molecular engineering of AMPs, the strategic exploitation of essential bacterial metabolic pathways, and the use of advanced controlled-release technologies.

Discussion

The findings of this review indicate that, although preclinical results are promising, most of these strategies—particularly siderophore–peptide conjugates—remain at an early stage of development, limiting their immediate clinical applicability.

The path to the clinical application of siderophore-drug and siderophore-peptide conjugates is still hindered by significant technical, regulatory, logistical, and economic challenges. From a technical perspective, the design of the covalent linker must fulfil two key requirements: extracellular stability and selective drug release within the bacterial cell. An imbalance between these two requirements may result in loss of activity owing to premature degradation, elimination through siderophore recycling, or ineffective intracellular retention. This challenge is further compounded by the diversity of intracellular pathways associated with different siderophore types.50,51

The synthesis of these molecular conjugates presents significant challenges, including multi-step synthetic processes, low yields, and the need for specialized reagents. These factors increase manufacturing costs and hinder large-scale production under Good Manufacturing Practice (GMP) standards. One example is the mycobactin–artemisinin conjugate, developed for the treatment of Mycobacterium tuberculosis infection, which combines promising antimicrobial activity with low production efficiency.11 Viable alternatives include heterologous expression in non-pathogenic hosts and green chemistry approaches, both aimed at reducing production costs and environmental impact.52

The current regulatory framework lacks specific evaluation pathways for these conjugates, which do not quite fit into the existing categories of small-molecule drugs or biologics. This results in delays to regulatory approval and increased development costs.53 Furthermore, effective clinical adoption requires diagnostic infrastructure to identify siderophore receptors and stable supply chains—resources that are limited in vulnerable settings.54

Another important barrier is the historically low return on investment in antibiotic development, which has discouraged investment from the pharmaceutical industry. Several alternative funding models have been proposed, including subscription-based payment models, push–pull incentives, and public–private partnerships.55,56

In the face of these challenges, some technological solutions have proven useful. The combination of these conjugates with nanotechnology-based delivery systems, such as liposomal encapsulation and polymeric nanoparticles, improves molecular stability and tissue distribution, while genetic engineering of biosynthetic pathways facilitates sustainable large-scale production.30,48 Global initiatives such as CARB-X and GARDP have already advanced preclinical development, demonstrating that collaboration among academia, industry, and policymakers is essential to translate these therapies from the laboratory to clinical practice.54,57

Study limitations

This narrative review, based on a systematic search, has inherent limitations, including the possible omission of relevant studies, heterogeneity among the sources analyzed, and the combined inclusion of preclinical and clinical evidence, which hinders the direct comparability of results. Furthermore, the absence of a formal quantitative analysis limits the ability to draw definitive conclusions regarding therapeutic efficacy.

In the face of antimicrobial resistance, conventional strategies prove to be insufficient, and biotechnology-based solutions are required. Siderophore–drug and siderophore–peptide conjugates exploit a mechanism essential to bacteria—iron uptake—as a selective entry pathway, with the potential to overcome permeability barriers, reduce systemic toxicity, and preserve commensal microbiota. The challenge extends beyond demonstrating clinical efficacy—already established for cefiderocol and increasingly supported by preclinical studies of other conjugates—to ensuring scalable manufacturing, appropriate regulatory frameworks, and equitable access. Achieving this will require close collaboration among academia, the pharmaceutical industry, and public health authorities. Siderophore conjugates provide a potential pathway for addressing the threat of a post-antibiotic era, and their clinical development requires a progressive, evidence-based approach.

Contribution to scientific literature

This review updates and synthesizes the available evidence on siderophore conjugates as a therapeutic strategy against multidrug-resistant Gram-negative bacteria. Unlike previous studies, which focused exclusively on the chemical or microbiological aspects of siderophore conjugates, this review also examines the public health challenges associated with scalability, regulation, and equitable access. It also presents the clinical evidence for cefiderocol alongside promising preclinical developments in a structured manner and discusses the limitations that may hinder their progression to clinical application. The manuscript was prepared in accordance with the PRISMA reporting guidelines to ensure the transparency and reproducibility of the literature search.

Ethical responsibilities

This manuscript is a literature review and does not contain or report clinical data from studies involving human participants or animal subjects conducted by any of the authors. Consequently, institutional review board or Research Ethics Committee approval was not required.

The authors declare that this manuscript is original, has not been previously published in whole or in part, and is not currently under consideration for publication elsewhere. Furthermore, all figures and tables are original or have been reproduced with the appropriate copyright permissions.

Statement on the use of artificial intelligence

During the preparation of this paper, Gemini 3 Flash was used to create schematic figures. After its use, the authors reviewed and edited the visual content as needed, assuming full responsibility for the content of the publication.

Funding

None declared.

CRediT authorship contribution statement

Alina Dammar Herrera-Callo: Writing – review & editing, Writing – original draft, Visualization, Validation, Supervision, Methodology, Investigation, Formal analysis, Data curation, Conceptualization. Marco Roberto Chávez-Morán: Conceptualization, Data curation, Formal analysis, Investigation, Methodology, Project administration, Resources, Software, Supervision, Validation, Visualization, Writing – original draft, Writing – review & editing.

Conflict of interest

Non declared.

Acknowledgments

The authors thank the Universidad Nacional de Frontera (Peru) for access to their bibliographic resources and the Central Library team for their support in retrieving scientific articles.

References
[1]
C.J.L. Murray, K.S. Ikuta, F. Sharara, et al.
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.
[2]
K.H. Luepke, K.J. Suda, H. Boucher, et al.
Past, present, and future of antibacterial economics: increasing bacterial resistance, limited antibiotic pipeline, and societal implications.
Pharmacotherapy, 37 (2017), pp. 71-84
[3]
U. Theuretzbacher, K. Outterson, A. Engel, A. Karlén.
The global preclinical antibacterial pipeline.
Nat Rev Microbiol, 18 (2020), pp. 275-285
[4]
L.S. Munoz-Price, L. Poirel, R.A. Bonomo, et al.
Clinical epidemiology of the global expansion of Klebsiella pneumoniae carbapenemases.
Lancet Infect Dis, 13 (2013), pp. 785-796
[5]
M. Tumbarello, E.M. Trecarichi, F.G. De Rosa, et al.
Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study.
J Antimicrobial Chemother, 70 (2015), pp. 2133-2143
[6]
D. van Duin, Y. Doi.
The global epidemiology of carbapenemase-producing Enterobacteriaceae.
[7]
GBD.
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis.
[8]
O'Neill J. Tackling drug-resistant infections globally: final report and recommendations the review on antimicrobial resistance chaired by Jim O'Neill. Published online 2016. [accessed 19 May 2026]. Available from: https://amr-review.org/sites/default/files/160525_Final%20paper_with%20cover.pdf.
[9]
G.R. Thomas, A. Corso, F. Pasterán, et al.
Increased detection of carbapenemase-producing enterobacterales bacteria in Latin America and the Caribbean during the COVID-19 pandemic.
Emerg Infect Dis, 28 (2022), pp. 1-8
[10]
Y. Yamano.
In vitro activity of cefiderocol against a broad range of clinically important Gram-negative bacteria.
Clin Infect Dis, 69 (2019), pp. S544-S551
[11]
K.H. Negash, J.K.S. Norris, J.T. Hodgkinson.
Siderophore–antibiotic conjugate design: new drugs for bad bugs?.
[12]
G.G. Zhanel, A.R. Golden, S. Zelenitsky, et al.
Cefiderocol: a siderophore cephalosporin with activity against carbapenem-resistant and multidrug-resistant Gram-negative bacilli.
[13]
B. Rayner, A.D. Verderosa, V. Ferro, M.A.T. Blaskovich.
Siderophore conjugates to combat antibiotic-resistant bacteria.
RSC Med Chem, 14 (2023), pp. 800-822
[14]
S.R. Choi, M.A. Hassan, B.E. Britigan, P. Narayanasamy.
Antimicrobial activity of Gallium(III) compounds: pathogen-dependent targeting of multiple iron/heme-dependent biological processes.
Curr Issues Mol Biol, 46 (2024), pp. 9149
[15]
J.A. Ramos-Castañeda, A. Ruano-Ravina, R. Barbosa-Lorenzo, et al.
Mortality due to KPC carbapenemase-producing Klebsiella pneumoniae infections: systematic review and meta-analysis: mortality due to KPC Klebsiella pneumoniae infections.
J Infect, 76 (2018), pp. 438-448
[16]
M.E. Falagas, C.M. Asimotou, M. Zidrou, D.S. Kontogiannis, C. Filippou.
Global epidemiology and antimicrobial resistance of Klebsiella pneumoniae carbapenemase (KPC)-producing Gram-negative clinical isolates: a review.
[17]
J. Jiang, L. Wang, Y. Hu, et al.
Global emergence of carbapenem-resistant hypervirulent Klebsiella pneumoniae driven by an IncFIIK34 KPC-2 plasmid.
[18]
N. Macesic, A.C. Uhlemann, A.Y. Peleg.
Multidrug-resistantGram-negative bacterial infections.
[19]
ECDC. Assessing the health burden of infections with antibiotic-resistant bacteria in the EU/EEA, 2016–2020. Published online 2022. [accessed 19 May 2026]. Available from: https://www.ecdc.europa.eu/en/publications-data/health-burden-infections-antibiotic-resistant-bacteria-2016-2020
[20]
WHO.
Global priority list of antibiotic-resistant bacteria to guide research, discovery, and development of new antibiotics.
WHO, (2017),
[21]
X. Zhen, C.S. Lundborg, X. Sun, S. Gu, H. Dong.
Clinical and economic burden of carbapenem-resistant infection or colonization caused by Klebsiella pneumoniae, Pseudomonas aeruginosa, Acinetobacter baumannii: a multicenter study in China.
Antibiotics (Basel), 9 (2020), pp. 514
[22]
W. Huang, F. Qiao, Y. Zhang, et al.
In-hospital medical costs of infections caused by carbapenem-resistant Klebsiella pneumoniae.
Clin Infect Dis, 67 (2018), pp. S225-S230
[23]
S. Imai, N. Inoue, H. Nagai.
Economic and clinical burden from carbapenem-resistant bacterial infections and factors contributing: a retrospective study using electronic medical records in Japan.
[24]
C.C. Murdoch, E.P. Skaar.
Nutritional immunity: the battle for nutrient metals at the host–pathogen interface.
Nat Rev Microbiol, 20 (2022), pp. 657-670
[25]
E. Arnold.
Non-classical roles of bacterial siderophores in pathogenesis.
Front Cell Infect Microbiol, 14 (2024),
[26]
A. Sánchez-Jiménez, F.J. Marcos-Torres, M.A. Llamas.
Mechanisms of iron homeostasis in Pseudomonas aeruginosa and emerging therapeutics directed to disrupt this vital process.
J Microbial Biotechnol, 16 (2023), pp. 1475-1491
[27]
A. Silale, B. van den Berg.
TonB-dependent transport across the bacterial outer membrane.
Annu Rev Microbiol, 77 (2023), pp. 67-88
[28]
H. Darmancier, Domingues CPF, J.S. Rebelo, et al.
Are virulence and antibiotic resistance genes linked? A comprehensive analysis of bacterial chromosomes and plasmids.
Antibiotics Basel, 11 (2022), pp. 706
[29]
H. Tahmasebi, S. Dehbashi, M. Nasaj, M.R. Arabestani.
Molecular epidemiology and collaboration of siderophore-based iron acquisition with surface adhesion in hypervirulent Pseudomonas aeruginosa isolates from wound infections.
[30]
Á.T. Gräff, S.M. Barry.
Siderophores as tools and treatments.
npj Antimicrob Resist, 2 (2024), pp. 47
[31]
C. Peukert, V. Gasser, T. Orth, et al.
Trojan horse siderophore conjugates induce Pseudomonas aeruginosa suicide and qualify the TonB protein as a novel antibiotic target.
[32]
Google.
Gemini 3 Flash [artificial intelligence model].
Google, (2026),
[33]
M.G.P. Page.
Siderophore cephalosporins.
[34]
C. Wang, D. Yang, Y. Wang, W. Ni.
Cefiderocol for the treatment of multidrug-resistant Gram-negative bacteria: a systematic review of currently available evidence.
[35]
S. Portsmouth, D. van Veenhuyzen, R. Echols, et al.
Cefiderocol versus imipenem-cilastatin for the treatment of complicated urinary tract infections caused by Gram-negative uropathogens: a phase 2, randomised, double-blind, non-inferiority trial.
Lancet Infect Dis, 18 (2018), pp. 1319-1328
[36]
Shionogi & Co. Ltd.
IDWeek 2023: shionogi presents new real-world evidence demonstrating effectiveness of earlier.
Shionogi & Co. Ltd., (2023),
[37]
Z. Lin, X. Xu, S. Zhao, et al.
Total synthesis and antimicrobial evaluation of natural albomycins against clinical pathogens.
[38]
C. Peukert, K. Rox, B. Karge, S.K. Hotop, M. Brönstrup.
Synthesis and characterization of DOTAM-based sideromycins for bacterial imaging and antimicrobial therapy.
[39]
R. Liu, P.A. Miller, M.J. Miller.
Conjugation of aztreonam, a synthetic monocyclic β-lactam antibiotic, to a siderophore mimetic significantly expands activity against Gram-negative bacteria.
ACS Infect Dis, 7 (2021), pp. 2979-2986
[40]
K. Krasulova, B. Neuzilova, K. Dvorakova Bendova, et al.
Preclinical characterisation of Gallium-68 labeled ferrichrome siderophore stereoisomers for PET imaging applications.
EJNMMI Radiopharm Chem, 9 (2024), pp. 1-17
[41]
C. Longshaw, A. Santerre Henriksen, D. Dressel, et al.
Heteroresistance to cefiderocol in carbapenem-resistant acinetobacter baumannii in the CREDIBLE-CR study was not linked to clinical outcomes: a post hoc analysis.
[42]
P. Viale, C.E. Sandrock, P. Ramirez, G.M. Rossolini, T.P. Lodise.
Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence.
Ann Intensive Care, 13 (2023), pp. 52
[43]
D. Melchiorri, T. Rocke, R.A. Alm, A.M. Cameron, V. Gigante.
Addressing urgent priorities in antibiotic development: insights from WHO 2023 antibacterial clinical pipeline analyses.
[44]
K. Krasulova, B. Neuzilova, K. Dvorakova Bendova, et al.
Preclinical characterisation of gallium-68 labeled ferrichrome siderophore stereoisomers for PET imaging applications.
EJNMMI Radiopharm Chem, 9 (2024), pp. 20
[45]
C.A. Roque-borda, P.B. da Silva, M.C. Rodrigues, et al.
Challenge in the discovery of new drugs: antimicrobial peptides against WHO-list of critical and high-priority bacteria.
Pharmaceutics, 13 (2021), pp. 773
[46]
K.S. Olascoaga-Del Angel, G. Sánchez-Evangelista, I. Carmona-Navarrete, et al.
Péptidos antimicrobianos, una alternativa prometedora para el tratamiento de enfermedades infecciosas.
Gac Med Mex, 154 (2018), pp. 681-688
[47]
L. Falcigno, S. Braccia, R. Bellavita, G. D'Auria, A. Falanga, S. Galdiero.
Metal-antimicrobial peptides combo: promising weapons to combat bacteria invaders.
[48]
C.A. Roque-Borda, P. Bento da Silva, M.C. Rodrigues, et al.
Pharmaceutical nanotechnology: antimicrobial peptides as potential new drugs against WHO list of critical, high, and medium priority bacteria.
[49]
C.A. Roque-Borda, L.M.D.G. Primo, K.P. Medina-Alarcón, et al.
Antimicrobial peptides: a promising alternative to conventional antimicrobials for combating polymicrobial biofilms.
[50]
V.C. Luo, M.W. Peczuh.
Location, location, location: establishing design principles for new antibacterials from ferric siderophore transport systems.
Molecules, 29 (2024), pp. 3889
[51]
P. Loupias, P. Laumaillé, S. Morandat, et al.
Synthesis and study of new siderophore analog-ciprofloxacin conjugates with antibiotic activities against Pseudomonas aeruginosa and Burkholderia spp..
[52]
H. Puja, G.L.A. Mislin, C. Rigouin.
Engineering siderophore biosynthesis and regulation pathways to increase diversity and availability.
Biomolecules, 13 (2023), pp. 959
[53]
N. Gargate, M. Laws, Khondaker, M. Rahman.
Current economic and regulatory challenges in developing antibiotics for Gram-negative bacteria.
npj Antimicrobials Resist, 3 (2025), pp. 1-17
[54]
L.J.V. Piddock, Y. Alimi, J. Anderson, et al.
Advancing global antibiotic research, development and access.
[55]
M. Anderson, D. Panteli, R. van Kessel, G. Ljungqvist, F. Colombo, E. Mossialos.
Challenges and opportunities for incentivising antibiotic research and development in Europe.
Lancet Regional Health – Europe, 33 (2023),
[56]
CIDRAP.
Un informe destaca los avances en los esfuerzos para incentivar la investigación y el desarrollo de antibióticos.
CIDRAP, (2024),
[57]
L.J.V. Piddock, J.P. Paccaud, S. O'brien, M. Childs, R. Malpani, M. Balasegaram.
A nonprofit drug development model is part of the antimicrobial resistance (AMR) solution.
Clin Infect Dis, 74 (2022), pp. 1866-1871
Copyright © 2026. Sociedad Española de Farmacia Hospitalaria (S.E.F.H)
Descargar PDF
Idiomas
Farmacia Hospitalaria
Opciones de artículo
Herramientas